Alopecia (Hair Loss)

Researchers are evaluating the use of a non-ablative 1470 nm laser for treating androgenetic alopecia and scarring alopecia in this single-center, open-label pilot study. The study aims to enroll up to 10 participants with biopsy-confirmed alopecia who seek improvement in hair loss. The study includes two treatment groups one for androgenetic alopecia and one for scarring alopecia, with five participants in each. Participants will receive up to three treatments using the Sciton HALO 1470nm non-ablative laser. Each treatment targets affected scalp areas and lasts approximately 10 to 15 minutes. Before treatment, a topical anesthetic and antiseptic cleaning are applied, followed by post-treatment care including topical betamethasone dipropionate cream. Treatments follow a set protocol to create controlled zones in the scalp skin to potentially enhance hair growth. Participants will have follow-up visits at months 6, 9, 12, and 15 after their initial treatment. During these visits, standardized photographs and hair density measurements using the Canfield HairMetrix device will be collected and compared to baseline. Participants will also complete questionnaires regarding pain, satisfaction, and self-assessment of hair growth. The study monitors safety and treatment effects over a total period of approximately 15 months.

Researchers are evaluating the effects of traditional Chinese herbal products on hair loss alopecia and gray hair canities in adults aged 18 to 60 years. This 6-month randomized, double-blind, placebo-controlled trial will enroll 152 participants, including some with gray hair, to study changes in hair count, density, and color. The trial aims to better understand how oral capsules and topical hair tonics may impact hair health. Participants will be randomly assigned to one of four groups, each receiving a combination of oral capsules and hair tonic or placebos for 24 weeks. The groups include VitaGreen Capsule A plus VitaGreen Tonic, VitaGreen Capsule B plus VitaGreen Tonic, Capsule Placebo plus VitaGreen Tonic, and Capsule Placebo plus Tonic Placebo. Treatments will be used as directed throughout the 24-week period. During the study, participants will attend three in-person visits at baseline, week 12, and week 24. Hair-related assessments include hair shedding counts, local hair counts, hair density, and photographic scoring of hair changes. A subset of participants with gray hair will have additional evaluations of hair color changes. Blood tests, urinalysis, and safety monitoring for adverse events will also be conducted. All clinical data will be collected for analysis, with the total participation lasting about six months.

This clinical trial focuses on adults aged 22 to 70 with androgenic alopecia, also known as male or female pattern hair loss. It aims to evaluate how well the Ultra device works and how safe it is for promoting hair regrowth by measuring improvements in hair density and hair shaft thickness. The study is sponsored by CynosureLutronic and involves no masking or blinding. Participants will receive six treatments using the Ultra device, which employs low level laser therapy on the scalp. These treatments are spaced about two weeks apart, with a small allowance of plus or minus three days. The study tracks changes from the start of treatment through to a 90-day follow-up after the final treatment. During the study, participants will be monitored for changes in hair density compared to their baseline levels. They will need to avoid significant hair changes like drastic haircuts or coloring and maintain their usual diet and exercise routines. The study requires adherence to visit schedules and restrictions on other hair growth treatments or medications. Safety and treatment effects are observed throughout the study period, which ends in December 2026.

Researchers are evaluating the safety and effectiveness of oral brepocitinib in adults with lichen planopilaris, a condition affecting the scalp. This Phase 23 trial aims to understand how well this medication works compared to a placebo in treating active and symptomatic lichen planopilaris. The study is sponsored by Priovant Therapeutics, Inc. and uses a randomized, double-blind design to ensure reliable results. Participants are randomly assigned to receive either oral brepocitinib or a placebo. The study is conducted in parallel groups, with neither the participants nor the researchers knowing who receives the active drug or placebo. The treatment period lasts 24 weeks, during which the participants take the assigned oral medication. The main goal is to measure improvement in the Investigator Global Assessment IGA score by Week 24. Throughout the study, participants will be regularly monitored for safety and symptom changes. Researchers will assess the proportion of participants who achieve significant improvement in their IGA scores at Week 24 and track changes in symptom severity using a numerical rating scale. The total study duration extends until July 2029, allowing for thorough evaluation of treatment effects and safety over time.

Central centrifugal cicatricial alopecia CCCA is a type of scarring hair loss mainly affecting middle-aged women of African descent. This condition causes patches of scarred scalp that grow larger over time, leading to brittle, shorter hair and symptoms like itching, pain, and tenderness. Since CCCA can cause permanent hair loss and distress, effective treatments are needed, but current options are limited and not well studied. This study evaluates the Revian Red All LED cap, a wireless device that uses two wavelengths of light 620 nm and 660 nm once daily for 10 minutes, to see if it can reduce inflammation, stop hair loss, and encourage regrowth in people with CCCA. Five women diagnosed with CCCA will use the cap daily for six months. Photos and dermatoscope images will be taken every two months to track changes in hairline and hair growth. Participants will complete questionnaires about their hair loss symptoms at each visit. The study measures include hairline stabilization and regrowth at multiple time points over six months. The research team aims to assess if this light therapy can help manage CCCA symptoms and hair loss. The entire study lasts six months, with ongoing monitoring and symptom evaluation during that time.

Researchers are studying the impact and burden of three skin conditions moderate or severe alopecia areata, non-segmental vitiligo, and moderate to severe hidradenitis suppurativa. The study includes adolescents and adults and aims to understand how these conditions affect quality of life and daily functioning in a large global population. This is an observational study where participants with each condition will have a single visit for data collection following routine clinical practice. No experimental treatments are given instead, the study gathers information during this one visit to assess disease characteristics and impact. During the visit, participants will complete questionnaires and clinical assessments specific to their condition. These include tools measuring symptom impact, hair loss severity, skin depigmentation, and quality of life related to each disease. This helps researchers better understand the real-world burden of these conditions. Participation involves only this one visit, with no long-term follow-up or additional procedures.

Researchers are evaluating the effectiveness and safety of baricitinib for treating severe or very severe alopecia areata, a form of hair loss, in children aged 6 to less than 18 years. This Phase 3 clinical trial aims to better understand how baricitinib works in this young population with this condition. The study is sponsored by Eli Lilly and Company and focuses on pediatric patients with a history of severe alopecia areata. Participants are randomly assigned to receive either a high dose or low dose of baricitinib taken orally, or a placebo. The study is divided into four periods a 5-week screening period to determine eligibility, a 36-week double-blind treatment period where participants receive the assigned study medication, an approximately 2-year long-term extension period for ongoing treatment, and a 4-week post-treatment follow-up. Some participants may continue treatment for up to a total of 180 weeks if eligible after the extension period. Throughout the study, participants undergo regular assessments including measurement of hair loss severity using the Severity of Alopecia Tool SALT score, patient-reported outcomes related to scalp hair and eyebroweyelash hair loss, and quality of life questionnaires. Safety and pharmacokinetics of baricitinib are also monitored. The primary outcome is to measure the percentage of participants achieving a SALT score of 20 or less by week 36. Participants receive careful monitoring during and after treatment, with the total study duration extending over multiple years.

Researchers are evaluating the effects of LAD603 in adults aged 18 to 65 with severe to very severe alopecia areata AA, a condition causing significant scalp hair loss. This Phase 2, randomized, placebo-controlled, and double-blind study aims to assess the efficacy of LAD603 on hair loss severity, as well as its safety, how the body processes the drug pharmacokinetics, immune response to the drug immunogenicity, and related biomarkers. Participants will be randomly assigned to receive one of three different doses of LAD603 or a placebo. Each treatment involves subcutaneous injections administered from Day 1 through Week 28. The study includes four groups LAD603 Dose A, Dose B, Dose C, and a placebo group. Treatments are given regularly during this 28-week period to monitor effects and safety. During the study, participants will have their hair loss severity measured using the Severity of Alopecia Tool SALT score at baseline and Week 28. Additional assessments include clinician-reported outcomes for eyelash and eyebrow hair loss at Week 28. Researchers will monitor safety, side effects, and immune responses throughout the 28 weeks. Participation involves regular visits for injections, assessments, and laboratory tests to collect relevant data on LAD603s impact and safety.

Researchers are evaluating the effects of LY4005130 in adults with severe alopecia areata, a condition causing significant hair loss. This phase 2 study compares LY4005130 with a placebo to see how well the drug works and how well participants tolerate it. Blood tests will be used to understand how the body processes the drug and its effects. Participants will receive either LY4005130 or a placebo, both administered intravenously into a vein. The study follows a randomized, double-blind design, meaning neither participants nor researchers know who receives the drug or placebo. The study lasts about 48 weeks, including screening. During the study, participants will undergo regular assessments including blood tests and scalp biopsies to track changes in hair loss severity and gene expression. The main measurement is the percentage of participants reaching a certain improvement in hair loss by week 24. Safety and side effects will be closely monitored throughout the study period.

Researchers are evaluating the use of human umbilical cord mesenchymal stem cell exosomes hUCMSC-sEV for treating androgenic alopecia, a common form of hair loss, in young men aged 18 to 35. This clinical trial aims to determine whether hUCMSC-sEV are effective and safe for this purpose. The study includes two phases a dose-finding Phase I and a randomized controlled Phase II comparing hUCMSC-sEV with minoxidil, a current hair loss treatment. In Phase I, participants receive injections of hUCMSC-sEV at three different dose levels, adjusted to the area of hair loss, with treatments given at weeks 0, 2, 4, and 6, followed by follow-up visits at weeks 8, 12, and 24. Phase II involves randomly assigning participants to either receive the optimal dose of hUCMSC-sEV injections at the same schedule or daily topical minoxidil applied for 12 weeks, with follow-up visits also at weeks 8, 12, and 24. Participants will attend clinic visits for treatments and assessments including measurements of hair density, hair diameter, and hair count from the first treatment up to 24 weeks. The trial monitors safety, tolerability, and hair growth outcomes over the study period. The total participation time spans approximately 24 weeks from initial treatment through follow-up assessments.